Safety, Tolerability and Abeta-specific Antibody Response of Repeated i.m. Injections of Adjuvanted CAD106 in Mild Alzheimer Patients

NCT01097096 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

177

Enrollment

INDUSTRY

Sponsor class

Conditions

Alzheimer's Disease

Interventions

BIOLOGICAL: CAD106
BIOLOGICAL: Placebo
BIOLOGICAL: Alum
BIOLOGICAL: MF59

Sponsor

Novartis Pharmaceuticals